C-Src is infrequently mutated in human cancers but it mediates oncogenic signals of many activated growth factor receptors and thus remains a key target for cancer therapy. However, the broad function of Src in many cell types and processes requires evaluation of Src-targeted therapeutics within a normal developmental and immunecompetent environment. In an effort to understand the appropriate clinical use of Src inhibitors, we tested an Src inhibitor, SKI-606 (bosutinib), in the MMTV-PyVmT transgenic mouse model of breast cancer. Tumor formation in this model is dependent on the presence of Src, but the necessity of Src kinase activity for tumor formation has not been determined. Furthermore, Src inhibitors have not been examined in an autochthonous tumor model that permits assessment of effects on different stages of tumor progression. Here we show that oral administration of SKI-606 inhibited the phosphorylation of Src in mammary tumors and caused a rapid decrease in the Ezh2 Polycomb group histone H3K27 methyltransferase and an increase in epithelial organization. SKI-606 prevented the appearance of palpable tumors in over 50% of the animals and stopped tumor growth in older animals with pre-existing tumors. These antitumor effects were accompanied by decreased cellular proliferation, altered tumor blood vessel organization and dramatically increased differentiation to lactational and epidermal cell fates. SKI-606 controls the development of mammary tumors by inducing differentiation.
Introduction
In breast cancer, Src is of particular interest as it is activated by both steroid hormone receptors and ErbB family growth factor receptors and activates transcription factors such as STAT3, STAT5 and b-catenin by direct phosphorylation (Silva and Shupnik, 2007; Kim et al., 2009) . Cellular Src was discovered in 1978 as the cellular counterpart of a viral gene, n-src, the transforming agent of Rous sarcoma virus (Spector et al., 1978) . This non-receptor tyrosine kinase belongs to a family of proteins that mediate signaling by a large number of growth factor receptors, integrins, G-protein-coupled receptors, hormones and stress responses implicated in multiple types of cancer and vascular biology (Criscuoli et al., 2005; Summy and Gallick, 2006; Kim et al., 2009) . Src is over-expressed and activated in many human cancers, including breast cancer, and its activation generally correlates with poor prognosis. Nonetheless, biomarkers predictive of a clinical response remain elusive.
The Src inhibitors dasatinib, saracatinib (AZD0530) and are in phase II of clinical development for the treatment of solid tumors of metastatic breast and prostate cancer. SKI-606, a multikinase inhibitor originally identified as an Src and Abl kinase inhibitor, is effective in vitro on colorectal and breast tumor cells, chronic myelogenous leukemia cells and also in multiple xenotransplantation experiments (Boschelli et al., 2001; Jallal et al., 2007; Vultur et al., 2008) . Src inhibitors generally have subtle effects on tumor cells under normal culture conditions (Golas et al., 2005; Vultur et al., 2008) . The effects of SKI-606 in models of developing breast cancer have not been reported.
The many functions of Src and Src family kinases in multiple signaling pathways suggest that the effects of inhibiting Src should be integrated into a wholeanimal context with a fully functional immune system (Finn, 2008) . The Src-dependent, immunocompetent, autochthonous FVB/N-Tg(MMTV-PyVmT)634Mul (MMTV-PyMT) breast cancer mouse model is an ideal tool for such a study because it permits the evaluation of both early and late stages of luminal-type metastatic carcinomas (Guy et al., 1992; Lin et al., 2003) . This model mimics changes associated with human breast cancer progression, including upregulation of cyclinD1 and HER2, and infiltration of leukocytes. PyMTinduced mammary tumors are dependent on multiple signaling molecules, including c-Src, phosphatidylinositol-3-kinase, Shc and insulin/insulin-like growth factor-1 receptors (Ishizawar and Parsons, 2004) .
Genetic inactivation of the c-src gene in MMTV-PyMT mice limits the effect of PyMT transgene expression on formation of hyperplastic lesions in mammary tissues after a long latency period with activated levels of c-Yes, a closely related member of the Src family of kinases (Guy et al., 1994) . c-Src activation by PyMT is not the sole driver for tumorigenesis, as expressing activated Src under the MMTV promoter in the absence of PyMT leads to defective mammary development and hyperplasia, but not invasive tumor formation (Webster et al., 1995) . Similarly, when PyMT is mutated to block either SHC or PI3kinase association, only hyperplastic lesions are formed (Webster et al., 1998) , unless an angiogenic stimulus such as vascular endothelial growth factor (VEGF) is provided .
Our studies show that SKI-606 treatment suppressed both early hyperplastic stages of the disease and overt tumor development. SKI-606 treatment stopped growth of established tumors by inducing dysplastic differentiation of tumor cells and altered vascular organization. These responses were accompanied by downregulation of the Polycomb repressor complex 2 subunit EZH2. The control of this aggressive model of breast cancer by differentiation suggests that different clinical end points might be considered to evaluate drugs that control cancer through differentiation rather than cell death.
Results

SKI-606 inhibits cell growth in culture without inducing cell death
Previous studies indicated that treatment with 1 mm SKI-606 significantly reduced phosphorylation of the Y418 gatekeeper residue of c-Src in human tumor cells (Golas et al., 2005; Vultur et al., 2008) . To determine whether SKI-606 affected in vitro growth of PyMTtransformed mammary tumor cells, Py-230 cells were treated with SKI-606 at various concentrations. In a 4-day assay, submicromolar concentrations of SKI-606 inhibited Py-230 cell proliferation ( Figure 1a ). However, Py-230 cells formed colonies from single cells in the presence of up to 750 nM SKI-606 ( Figure 1a ), but colony size was significantly reduced (Figure 1b ), suggesting that SKI-606 inhibited proliferation of Py-230 cells without significant cytotoxic effects. Phosphorylation of Src Y418 was inhibited by 1 mM SKI-606 without affecting the total amount of Src protein (Figure 1a , right, lane 3) while 0.1-mM SKI-606 had little effect. Y418 phosphorylation is required for full activity (Kmiecik and Shalloway, 1987) and thus, the extent of Y418 phosphorylation is an estimate of the maximum required concentration of a compound that fully inhibits Src.
SKI-606 accumulates in tumor tissue and inhibits Src activity
Previously published data indicated that orally administered SKI-606 was well distributed in the tissues of nude mice and accumulated in human tumor xenografts. Analysis of plasma obtained from MMTV-PyMT tumor-bearing mice 18 h after a single oral dose of SKI-606 revealed plasma concentrations of 321 ng/ml (604 nM), well above the concentration effectively inhibiting Src kinase activity (Boschelli et al., 2001) and well within the range required to inhibit breast cancer tumor cell growth and invasion in cell culture (Jallal et al., 2007; Vultur et al., 2008) (Figure 1c ). In addition, SKI-606 accumulates in PyMT tumors to a concentration of 2477 ng/g of tumor ( Figure 1c ). We determined the relative levels of active Src in these tumors by monitoring the phosphorylation of Y418 18 h following SKI-606 administration. SKI-606 treatment reduced P-Y418 levels in PyMT tumors by 75% of the levels observed in tumors from vehicle-treated animals ( Figure 1d ), suggesting that SKI-606 inhibits the intended molecular target.
SKI-606 suppresses mammary tumor appearance
PyMT expression occurs about 4 weeks after birth upon mammary gland development at sexual maturity. The mammary epithelial tree of MMTV-PyMT adolescent females develops a small tumor-like mass beneath the nipple area concurrent with the emergence of the normal epithelial branching tubes (Neznanov et al., 1999; Maglione et al., 2001) . Next focal hyperplastic lesions arise among the normal epithelial structures, which then progress to mammary intraepithelial neoplasia and later to invasive cancer (Maglione et al., 2001; Lin et al., 2003) .
To test the effect of SKI-606 on both early hyperplastic lesions and mammary epithelial development, SKI-606 (150 mg/kg) was administered by oral gavage to female transgenic mice aged 30 ± 2 days once daily for 14 days. SKI-606 treatment was very effective in limiting the growth of hyperplastic lesions and mammary intraepithelial neoplasia to less than 40% of the size of lesions in the vehicle-treated control group ( Supplementary Figures S1A and S1C ). In contrast, the normal mammary epithelial ductal and endbud structures appeared fully extended to the distal limits of the fat pad. This indicates that SKI-606 did not interfere with the normal invasion and branching of the mammary gland while restricting abnormal hyperplastic growth. Histological analysis revealed that the residual dysplastic mammary tissue of the SKI-606treated animals had less solid tumor cell mass and increased cystic epithelial structures (Supplementary Figures S1Ba-d ). Blood vessels of the mammary tissues of SKI-606-treated animals were closely associated with the organized cystic epithelia (Supplementary Figures S1Be and f). The close juxtaposition of vessels and expanded cystic epithelia resembles the tissue structure observed in pregnant animals .
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To test the effect of SKI-606 on full tumor development, two groups of female MMTV-PyMT mice were administered SKI-606 (150 mg/kg) or vehicle by oral gavage at age 30±2 days for up to 45 additional days on a schedule of five consecutive daily treatments followed by 2 days without treatment. All animals tolerated SKI-606 administration and SKI-606-treated animals could not be distinguished from the control group by weight ( Figure 2 ). All control animals developed palpable tumors at ages between 38 and 55 days ( Figure 2B ). No tumors were detected in SKI-606-treated mice until the age of 60 days and only half of the treated animals developed obvious tumors by 75 days. On termination of treatment, only a few SKI-606-treated mice had tumors that could be recovered by dissection and none of these animals developed metastases in the lungs. The entire mammary glands of animals without grossly apparent malignancies were dissected from both groups and compared by weight. Figure 2C shows that SKI-606 treatment resulted in less dense mammary tissue than that observed with tissue from vehicle-treated animals (P ¼ 0.002). Histological analysis revealed that mammary glands from SKI-606-treated animals had large fluid-filled cysts ( Figure 2Dc ) with a less extensive distribution. These results revealed SKI-606's remarkable antitumor efficacy with less than half of the animals developing overt, discrete tumors in this highly aggressive tumor model. Furthermore, mammary glands from SKI-606-treated mice had dysplastic but more differentiated cystic structures containing milk protein. To test the effect of SKI-606 treatment on developed mammary tumors, animals with tumor sizes of 0.6-1 cm in diameter were treated for 14 consecutive days. Tumors of control animals continued to grow steadily with increasing variability in tumor size over time ( Figure 3A) . In contrast, tumors in SKI-606-treated mice did not increase in size. After 2 weeks of treatment, the excised tumor weights were approximately half that of tumors from the control group ( Figure 3B ). Staining of proliferative cell nuclear antigen (PCNA) revealed that tumors from SKI-606-treated mice were not as mitotically active ( Figure 3C ). Histological examination showed the typical high nuclear density and undifferentiated state of PyMT tumors (Figures 3A, Db and Dg) . By contrast, SKI-606-treated tumors were heterogeneous with areas of higher nuclear density mixed with more epithelial glandular and papillary type structures (Figures 3Dc and Dd) . Some tumors had cysts lined by stratified squamous epithelium that produced copious laminated keratin debris. This type of differentiation has been previously observed with some types of MMTV-PyMT crosses and in Wnt-induced mammary tumors Rosner et al., 2002) . Cystic areas of the tumors also contained abundant b-casein protein (Figure 3Dh ). Of the six animals of each group that were inspected for lung metastases, five of each group were found to have metastases. The 2-week SKI-606 treatment did not change the average of three metastases per lung per group, which likely existed before treatment start (Kouros-Mehr et al., 2008) . The sizes of the metastases were similar in both groups. The small size of most of the metastases prevented a definitive conclusion regarding differences in differentiation state.
PyMT tumors develop as expansions of keratin 8 (K8)-positive luminal epithelial cells lined by some keratin 14 (K14)-positive myoepithelial cells at early stages ( Figure 4A ). The cystic structures induced by SKI-606 treatment contained both luminal K8-positive epithelial cells and K14-positive basal-like cells. These structures of SKI-606-treated tumors differed from normal mammary glands by occasional penetration of the luminal layer with K14-positive cells (Supplementary data, Figure S2A ) and by the lack of smooth muscle Figure S2C ). This differentiated state was not accompanied by an increase in apoptosis assessed by DNA end labeling (Supplementary Figure S2B ). Furthermore, the estrogen receptor (ER) was found to be associated with the highly proliferative outer rim of tumors and within stromal cells (Supplementary Figure S2D) . The nuclear ER at the outer margin of tumor masses and within many of the organized epithelia was not diminished by SKI-606 treatment (Supplementary Figure S2D ).
SKI-606 treatment induces remodeling of mammary tumor vasculature
To determine the impact of SKI-606 on PyMT tumor vascularity, we stained tumor sections with anti-CD31.
The vascular network of the vehicle-treated tumors displayed a chaotic organization ( Figure 4C , left). Control tumor vessels were largely dilated and the endothelium was thick or extended, resulting in severe vessel deformation. These vessel abnormalities are hallmarks of the tumor vasculature (Cheung et al., 1997; Jain, 2005) . SKI-606 treatment resulted in significant remodeling of the tumor vasculature after 14 days of treatment. The vascular network of SKI-606treated mammary tumors exhibited reduced dilation ( Figures 4C and D) and a thinner vessel endothelium ( Figure 4C , right), minimizing vessel deformation. Furthermore, the vessels in the SKI-606-treated tumors appeared to be more evenly distributed than those in control tumors ( Figure 4C ). Although SKI-606 induced significant structural remodeling of the vessels, it did not affect the overall tumor vessel density (Figure 4D , . SKI-606 treatment may directly or indirectly induce normalization of the tumor vasculature as observed in the vascular normalization phenomenon induced by VEGF blockade-based antiangiogenic therapies (Jain, 2005) .
Gene expression changes associated with SKI-606 treatment
The RNAs of eight tumors each from SKI-606-and vehicle-treated mice were analyzed for gene expression changes on two different array platforms (Illumina bead arrays, Affymetrix arrays) to identify the most robust gene expression changes. Data are available from the GEO accession numbers GSE20921 and GSE22150. Given the histological variation, the list of genes that were significantly changed in both arrays was small ( Supplementary Table S1 ). Comparison of the 34 genes altered by SKI-606 treatment with other array results resulted in identification of multiple studies with similar gene expression changes ( Supplementary Table S2 ).
In four examples, SKI-606-induced genes were decreased in cancer cells. Increased expression of these genes in SKI-606-treated tumors is consistent with reversing the cancer phenotype. Twelve of the 34 SKI-606-induced genes were increased in lactating normal mammary gland. These results are consistent with the increased casein level and increased epithelial differentiation of SKI-606-treated tumors. Examination of keratin gene expression in individual tumors and their corresponding histological appearance revealed that increased expression of keratin genes was associated with only three of the eight tumors (Figures 5a and b ). However, each of those tumors with increased K5, K7, K14 and K17 also had areas of epidermal-like differentiation (Figure 5c , tumors 737, 787 and 698). These results suggest that PyMT tumors do not respond uniformly to SKI-606, but rather may adopt distinct differentiated fates or respond asynchronously depending on their particular microenvironment.
Western blot analysis of four of the six serum samples from tumor-bearing animals treated with SKI-606 for 14 days had elevated casein protein levels, while none of the six samples from tumor-bearing control mice showed similar casein levels (Supplementary data, Figure S5 ). The casein signal was comparable to serum levels found in lactating mothers (Supplementary Figure  S5B, lanes 8 and 9) . These results suggest that a blood test may provide information about the differentiation response.
SKI-606 treatment reduces Ezh2 expression
The Ezh2 and increased expression is associated with reduced E-cadherin levels . SKI-606 treatment increases E-cadherin stability in colorectal tumor cells and E-cadherin localization at the plasma membrane in several cell types (Coluccia et al., 2006; Jallal et al., 2007; Vultur et al., 2008) . Given these relationships, and the profound responses in the SKI-606-treated mice, we examined the effects of SKI-606 on Ezh2 levels. Ezh2 levels of tumors 18 h after a single dose of SKI-606 were measured by immunoblot analysis. Ezh2 levels were reduced by approximately 50% in SKI-606-treated samples (Figures 6A and B ). In addition, RT-PCR analysis of RNA from tumors excised from mice 8 h after SKI-606 administration revealed a 50% reduction of Ezh2 mRNA ( Figure 6B ). E-cadherin mRNA levels increased after a single treatment with SKI-606 ( Figure 6B ). Immunohistochemical analysis revealed high and nearly uniform expression of Ezh2 in the MMTV-PyMT tumor lobes. This expression was decreased in tumors from animals treated with SKI-606 just once (Figure 6Ca ), (Supplementary data, Figure S4 ). Furthermore, decreased Ezh2-staining appeared to correlate with portions of the tumors that had adopted a more epithelial morphology (Figures 6Cc  and Cd, arrows) . In tumors treated for 14 days, Ezh2 was greatly diminished ( Figure 4B ; Supplementary  Figure S3 ). E-cadherin staining was very strong in the differentiated epithelial cysts formed following 14 days of treatment ( Figure 4B; Supplementary Figure S3 ). In tumor samples with epidermal differentiation, Ezh2 was localized in the presumptive proliferative cells surrounding the focal keratin differentiation. E-cadherin localization appeared adjacent to Ezh2 in these areas (Supplementary data, Figure S3 , sample 2241). This organization of Ezh2 and E-cadherin is similar to that observed during normal epidermal development (Ezhkova et al., 2009) . These data show that a key developmental regulatory protein decreases rapidly after SKI-606 exposure and its loss is associated with increased E-cadherin RNA and more organized epithelium. 
Discussion
Treatment of adolescent MMTV-PyMT females for 4 weeks effectively prevented palpable tumor formation in half of the SKI-606-treated animals. Instead of residual solid tumors, distended and dysplastic mammary cysts with accumulated casein protein filled the fat pads. The differentiation-inducing effect of SKI-606 was most dramatically demonstrated by the 2-week treatment of tumor-bearing animals. This resulted in enrichment of organized K14-positive basal epithelia juxtaposed with luminal epithelial cells in cystic structures, the accumulation of milk protein and sporadic epidermal differentiation. Strikingly similar observations of cystic buildup of milk proteins were reported for Src null mice, which were ascribed to a defect in secretory activation during pregnancy (Watkin et al., 2008) .
The relatively small list of differentially expressed genes in SKI-606-treated tumors is likely because of the variation in differentiation of individual tumors that decreased the probability of passing multiple statistical thresholds. Genes whose expression was increased in all SKI-606-treated tumors overlapped significantly with genes increased during lactation (Rudolph et al., 2007) 
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L Hebbard et al and were repressed in mouse transgenic tumors caused by c-Myc, SV40 T antigen and ETV6-NTRK3 (Klein et al., 2005; Bild et al., 2006; Li et al., 2007) and human breast cancer cell lines (Klein et al., 2005) . These results suggest that the SKI-606-induced differentiation reflects the reversal of a common transcriptional response to oncogene transformation. The induction of differentiation by SKI-606 may be related to the function of Src in ER signaling (Ishizawar and Parsons, 2004) . Cross talk between ER and Src is well documented and may include effects on the nuclear localization of ER. Src null mice have defects in mammary gland development and ER signaling (Kim et al., 2005b) . Although we found no differences in the cellular distribution of ER in both tumor cells and stromal cells of mice treated with SKI-606, alterations in ER activity may still contribute to the diverse differentiation responses observed. Differentiation of SKI-606-treated PyMT tumors was associated with changes in vascular organization, although not with vascular density. Src is involved in the production of VEGF (Mukhopadhyay et al., 1995) and Src is activated by VEGF receptors (Eliceiri et al., 1999) . Significantly, the observed changes in vascular organization after SKI-606 treatment are consistent with normalization of the more permeable and tortuous vessels found in these tumors (Cheung et al., 1997) . SKI-606 treatment reduces tumor cell extravasation (Weis et al., 2004) at least in part by strengthening VE-cadherin (cadherin 5) and b-catenin interaction. SKI-606 was also effective in models for ischemic stroke wherein VEGF-induced vascular leakage mediated by Src activation is believed to have a dominant role in disease etiology. These observations suggest that Src inhibition by SKI-606 contributes to tumor vascular normalization. Although SKI-606 was originally developed as an Src inhibitor, subsequent studies indicated that it targets multiple kinases, including Abl kinases (Remsing Rix et al., 2009) . At the RNA level, Lck, Egfr and Csk are expressed at detectable levels in PyMT tumors and are reported to have an SKI-606 IC 50 of 100 nM or less (Remsing Rix et al. 2009 ). However, the observed biological responses to SKI-606 treatment are consistent with existing knowledge of the roles of Src in angiogenesis, tumor cell survival, proliferation and motility (Finn, 2008) . Src inhibition alone may be responsible for a large part of the observed biological effect on these tumors.
Apoptosis outside of the obviously necrotic areas was not increased significantly in tumors treated for either 18 h (data not shown) or 2 weeks. Thus, the response of tumor cells to SKI-606 appears to be decreased proliferation, but not elevated cell death. Within tumor cells, Src binds to and mediates the oncogenic signaling of Polyoma middle T antigen (Courtneidge and Smith, 1983) . Although the presence of Src is required for PyMT-induced tumors to form in the mammary gland (Guy et al., 1994) , deleting Src is not equivalent to inhibiting its kinase activity, as demonstrated by partial restoration of osteoclast function by expression of catalytically inactive Src in Src-deficient osteoclasts (Schwartzberg et al., 1997) . SKI-606 treatment for 4 weeks resembles the result of genetically inactivating Src. This is consistent with Src inhibition being an important mediator of the effects of SKI-606.
PyMT activates both Src and PI3 kinase pathways, much like the combination of ErbB2 and ErbB3 signaling. Src is also activated by ErbB2 receptor signaling , directly associates with the same receptor (Kim et al., 2005a) and facilitates the heterodimerization of ErbB2 and ErbB3 (Ishizawar et al., 2007) . Thus, SKI-606 might be expected to have similar effects on ErbB2-driven mammary tumors as those observed here for PyMT-driven tumors.
Ezh2 is a core component of the Polycomb Repressive Complex 2 that mediates gene repression by methylating lysine 27 on histone H3 and recruiting histone deacetylase (Bracken and Helin, 2009) . Polycomb Repressive Complex 2 may maintain pluripotency by silencing developmental regulators that drive differentiation (Lee et al., 2006) . Poorly differentiated human tumors show preferential repression of Polycomb Repressive Complex 2regulated genes and this expression pattern is associated with poor clinical outcome. There is a strong correlation between elevated Ezh2 levels and poorly differentiated breast carcinomas (Kleer et al., 2003) . Deregulated expression of Ezh2 and its downstream target genes may have a critical role in maintaining the arrested differentiation phenotype observed in aggressive tumors.
Treatment of MMTV-PyMT tumors with SKI-606 resulted in a rapid reduction in Ezh2 protein, and a modest increase in E-cadherin mRNA, as might be expected from the transcriptional inhibition of the E-cadherin promoter by Ezh2, . However, E-cadherin protein and RNA are expressed within PyMT tumor cells, suggesting that Ezh2 is not sufficient to silence E-cadherin in this system. SKI-606 may alter Ezh2 levels indirectly through miR-101, a group of microRNAs that have been shown to negatively regulate Ezh2 levels (Varambally et al., 2008) . The relatively rapid inhibition of Ezh2 expression following SKI-606 treatment is consistent with a functional and early role of Ezh2 rather than only a reflection of the later differentiated state of treated tumors. This is not likely only due to an antiproliferative effect because a single treatment with SKI-606 for 18 h did not result in a significant decrease in the Proliferative Cell Nuclear Antigen labeling index (not shown), even though Ezh2 protein was clearly decreased. Over-expression of Ezh2 in the mouse mammary epithelium leads to intraductal hyperplasia and delayed involution (Li et al., 2009) . Similarly, MMTV-driven expression of activated Src caused mammary hyperplasia and arrested lobuloalveolar development (Webster et al., 1995) , suggesting that both proteins may cooperate to restrict the cell fates and maintain the undifferentiated cellular phenotypes that are common in aggressive breast cancers. The restriction of MMTV-PyMT tumors by SKI-606-induced differentiation may be mediated by both tumor and host cell responses. The restriction of mammary tumor progression by induced differentiation is a relatively rare example that stimulates consideration of differentiation SKI-606 induced tumor differentiation L Hebbard et al therapy. It will be of great interest to determine the link between Src inhibition and Ezh2 expression in developing breast cancer.
Materials and methods
Antibodies
The antibodies used were keratin 8 (TROMA1, Developmental Studies Hybridoma Bank, University of Iowa, IA, USA), keratin 14 (PRB-155P, Covance, Princeton, NJ, USA), CD31 (Pharmingen, 01951D, BD Bioscience, San Jose, CA, USA), Proliferative Cell Nuclear Antigen (P8825, Sigma-Aldrich, St Louis, MO, USA), smooth muscle actin (Sigma-Aldrich, C6198), EZH2 (6A10, Novocastra, Leica Microsystems, Bannockburn, IL, USA) and AC22 (Cell Signaling Technologies, Danvers, MA, USA), E-Cadherin, Clone 24E10 (Leica Biosystem, Bannockburn, IL, USA) and Alexa 488 donkey anti-rabbit IgG (Molecular Probes A21206, Invitrogen, Carlsbad, CA, USA), Alexa 568 goat anti-rat IgG (Invitrogen 11077), HRP anti-mouse IgG (Dako Envision system, Dako North America, Inc., Carpinteria, CA, USA) and anti-rabbit IgG (Vector ImmPRESS, Vector Labs, Burlingame, CA, USA).
The Py-230 cell line was isolated from a MMTV-PyMT tumor by Dr Leslie Ellies and grown in F12K media (Mediatech, Manassas, VA, USA), supplemented with 5% fetal bovine serum and MITO growth factor supplement (Fisher CB50006). Cell numbers were determined by imaging methanol-fixed cells grown for 4 days in a 96-well plate stained with 4 0 ,6-diamidino-2-phenylindole (DAPI) using the Beckman IC-100 imagining equipment and Cytoshop software. Data of nine images per well and triplicate wells were used to calculate total cell numbers.
Animal procedures
The transgenic MMTV-PyMT mouse on the FVB/N genetic background was obtained from Dr William Muller (Guy et al., 1992) . Genotypes were determined as previously described (Man et al., 2003) . Tumor analysis was performed as previously described (Neznanov et al., 1999; Liu et al., 2005) . SKI-606 was formulated in 0.5% methocellulose and 0.4% Tween 80 and administered by oral gavage at 150 mg/kg. Hyperplastic areas of whole-mounted mammary glands were measured from images converted to gray scale. Total pixel areas of threshold images were measured using Image J public domain software. Statistical tests were performed within the Prism suite of tests. SKI-606 levels in plasma were determined as previously described (Boschelli et al., 2001) .
Histology
Apoptosis was detected using terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling of hydrolyzed nuclear DNA (ApopTag, Millipore Co., Billerica, MA, USA). Antigen retrieval was performed in citrate buffer at pH 6 on zinc-formalin (Z-fix, Anatech, Battle Creek, MI, USA) fixed paraffin-embedded tissues. K8, K14, smooth muscle actin and CD31 were detected with acetone-fixed, sucrose infused, OCT embedded, frozen sections. Volocity software (Improvision, PerkinElmer, Waltham, MA, USA) was used to determine blood vessel area, perimeter and density. Four tumors were analyzed for each group using seven random areas from each tumor section. Over 3000 tumor blood vessels were individually analyzed in total for each group.
Protein and RNA analysis Immunoprecipitation and western blot analysis was performed as described (Jallal et al., 2007) . Quantitative real-time PCR was performed with FAM-labeled TaqMan probe sets specific for mEzh2 (Mm00468464_m1) or b-Actin (Mm01205647_g1) from Applied Biosystems. Cdh1 RNA was independently measured using methods that were previously described (Galang et al., 2004) .
Gene expression array analysis RNA was analyzed with Illumina MouseRef-8 BeadChips using the manufacturer's BeadArray Reader and Scanner and BeadStudio software. In addition, an additional set of tumors from control and test groups was analyzed using Affymetrix chips and procedures. Data analysis was done in three stages. First, expression intensities were calculated for each gene probed on the array for all hybridizations (26 in total) using Illumina's Beadstudio #1 software. Second, intensity values were quality controlled and normalized; quality control was carried out by using the Illumina Beadstudio detection, P-value set to be 0.1 as a cutoff. This removed genes that were not detected. All the arrays were then normalized using the normalize quantiles routine from the Affymetrix package in Bioconductor. These normalized data were imported into GeneSpring and analyzed for differentially expressed genes. The groups of biological replicates were described to the software, and significantly differentially expressed genes were determined based on t-tests and fold difference changes in expression level. Primary data is deposited in GEO database under accession numbers: GSE20921 and GSE22150.
